Pharma Services

Accelerating diagnostic and therapeutic
research to improve patients’ lives

At a glance

Enabling accurate patient selection and monitoring

Integrated access to imaging agents enhancing study validity and efficacy through precision stratification

Confidence in patient scheduling

Reliable and efficient manufacturing and delivery help ensure on-time study results and reduced patient wait times

Consistent results when scaling

Established global network of clinical partners and supply channels enabling standardization & flexibility as needed

Simplified study management powered by collaboration

Tailored wing-to-wing expertise to support streamlined communication, contracting and execution

Providing access to expertise, manufacturing, products and services to enable precisely targeted trials

As pharmaceutical and research organisations strive to accelerate the next generation of disease treatment and enhance the understanding of therapeutics, accurate patient selection and reliable data quality will be fundamental success levers for attaining optimal findings.

To find out more, please contact us at pharma.services@ge.com

Features

Providing access to expertise, manufacturing, products & services to enable precisely targeted trials for tracers & therapies

Chronic illnesses destroy lives of both sufferers and caregivers. Despite pioneering research to create disease modifying therapeutics in neurology, cardiology and oncology care areas, there are still significant advancements yet to be made to help patients overcome these complex diseases.

Enabling Accurate Patient Selection and Monitoring

Utilizing imaging tracers for precise patient selection ensures selecting the right individuals for your cohort. This approach can help save costs, remove non-responders, and demonstrate higher effectiveness. Imaging agents can be applied as required, either during initial patient selection or for monitoring disease progression over time in clinical trials.

Enabling Accurate Patient Selection and Monitoring

15,000+

Doses delivered for clinical trials worldwide since 2012

30+

Products across care areas and modalities

Confidence in Patient Scheduling

A dependable partner is essential for screening readiness. With a 97%* delivery success rate in our supply chain, we work round-the-clock to support your studies. GE HealthCare has enabled over 300 studies, ensuring on-time study results and reduced patient wait times.

Confidence in Patient Scheduling

97%

Success for global imaging agent deliveries*

300+

Clinical studies within 15 years

Consistent Results When Scaling

GE HealthCare offers an established global network of clinical partners with a footprint of over 500 imaging sites and supply channels across over 30 countries. This allows the flexibility to accommodate the geographical needs and to explore options for supply into new regions.

Consistent Results when Scaling

500+

Imaging sites supplied to in total

30+

Countries supported for dose supply

Simplified Study Management Powered by Collaboration

GE HealthCare provides a single point of contact across several functional stakeholders providing a simplified, seamless and integrated end-to-end service to manage study dose supply across the globe. This service model includes streamlined contracting, centralized billing/invoicing and project tracking through regular meetings.

Simplified Study Management Powered by Collaboration

Functions streamlined

Single Point of Contact

Partnering with you across all care areas

Neurology

To learn more about neurology solutions contact
pharma.services@ge.com

Oncology

To learn more about oncology solutions contact
pharma.services@ge.com

Cardiology

To learn more about cardiology solutions contact
pharma.services@ge.com

Digital

To learn more about digital solutions contact
pharma.services@ge.com

References

https://www.who.int/news-room/fact-sheets/detail/dementia

https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)

https://www.cancerresearchuk.org/health-professional/cancer-statistics/worldwide-cancer

^{*2022, Global SPECT GE HealthCare data.}

We’re sorry, a problem occurred with the form. Please try again.

Thank you for your inquiry.

We will be in touch soon.

Something went wrong

We will check and get back.

Try Again

JB26387XX November 2023